|
ADRAFINIL
to order (prescription
not required)
Adrafinil (Olmifon®) a French stimulant and
antidepressant belongs to a unique class of drugs called “Eugeroics”
(meaning good arousal).
Adrafinil helps to improve brain chemical processes without
affecting heart rate or pressure and was specifically designed to treat
narcolepsy (sleeping in the daytime), as such it can enhance awareness, mental
clarity and alertness, allowing the individual to remain both alert and awake
during the day.
Adrafinil's unique feature is that it only arouses when
stimulation is required. This is achieved by increasing the receptiveness of
brain alpha-1 receptors to noradrenaline. This unique action even allows the
individual to sleep if he or she so requires.
One or two tablets (300mg each) are taken twice a day, as
required (also
see Modafinil).
"Adrafinil changed my life giving me drive and
direction."
J.C., California
HOME
to
order adrafinil
research
ADRAFINIL (Olmifon®)
Composition
Adrafinil; Corn starch, modified sodic
carboxymethyl-cellulose, polyvidone excipient, glycerol, magnesium steate, talc,
lactose, polyoxyethylene glycol 4000, titanium dioxide, polymethly acrylate
glycerol.
Information for the User
This product is a psycotonic. It is recommended
for elderly patients who have difficulty staying alert and who suffer from a
general slowing down of mental activity.
Warning
1. The effectiveness of Olmifon® has not yet
been tested on the non-elderly.
2. This preparation contains an active ingredient, which could induce a positive
result in anti-doping tests for athletes.
Caution
If you suffer from epilepsy, or serious hepatic
or renal disorders, consult your doctor before taking this product. Do not
hesitate to seek advice from your doctor or chemist, if there is any chance of
an interaction-taking place between different medicines. Any additional
treatment should be reported, especially if you are taking neuroepileptic
medicines. Keep this and all other medicines safely out of the reach of
children.
Side Effects
As with any active product, this medicine may
possibly cause side effects. Headache, stomach pains and skin irritations have
been reported in clinical tests, and in certain cases, inner tension.
Directions
2 to 4 tablets daily. Please follow your doctor's
instructions.
Prescription Conditions
This product has been prescribed for you in order
to remedy a particular medical problem. Do not use it to treat other ailments.
Do not use it again without first consulting your doctor. Do not use it to treat
another person. Consult your doctor.
HOME
to
order
A unique psychopharmacologic profile of
adrafinil in mice
Rambert FA, Pessonnier J, de Sereville JE, Pointeau AM, Duteil J
The following psychopharmacological effects of adrafinil have been observed in mice:
increase in locomotor activity (64-256 mg.kg-1), antagonism (16-128 mg.kg-1) of the
hypnotic effects of barbitone but not of pentobarbitone, reduction of immobility duration
in the forced swimming test (16-256 mg.kg-1); slight antagonism (256 mg.kg-1) of
electroshock-induced convulsions; no modification of rectal temperature; no stereotyped or
climbing behaviour; no increase in lethality in aggregated mice (LD50 isolated = 1022
mg.kg-1, LD50 aggregated = 859 mg.kg-1); lack of effects on the provisional tests for
antidepressants: no interaction with reserpine-, oxotremorine-, or apomorphine-induced
hypothermia but potentiation of yohimbine-induced toxicity; lack of
peripheral sympathetic effects (no mydriasis, no salivation, no contraction of the
pilomotor muscles, no antagonism of reserpine-induced ptosis); lack of peripheral
anticholinergic effects (no mydriasis, no antagonism of oxotremorine-induced salivation or
lacrimation). As compared to no analeptic, anticholinergic or antidepressant drugs,
adrafinil shows a unique behavioural profile in mice defined on the one hand by a specific
stimulant activity associated with antidepressant-like
effects that do no seem related to a
beta-adrenergic mechanism and on the
other hand by a lack of dopaminergic effects. Most adrafinil-induced effects (increase in
locomotor activity, reduction of immobility duration in the forced swimming test) may
correspond to a central alpha 1-adrenergic stimulation, but the unexpected lack of
peripheral sympathetic effects remains unexplained.
PMID: 3713198, UI: 86229117
J Pharmacol 1986 Jan-Mar;17(1):37-52
HOME
to
order
|
